Overview

A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis

Status:
NOT_YET_RECRUITING

Trial end date:
2025-09-30

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to learn if drug CGB-500 works to treat atopic dermatitis in subjects 12 years of age or older. It will also learn about the safety of CGB-500. The main questions it aims to answer are: Does CGB-500 decrease the severity of atopic dermatitis on the skin? What medical problems do participants have when taking drug CGB-500? Researchers will compare CGB-500 to a an approved product (1.5% ruxolitinib) to see if CGB-500 works to treat atopic dermatitis. Participants will: Apply CGB-500 and ruxolitinib to different locations on their body twice a day for four weeks. Visit the clinic six times for checkups and tests Keep a diary of their symptoms and when they apply the product

Phase:

PHASE2

Details

Lead Sponsor:

CAGE Bio Inc.

Treatments:

ruxolitinib
tofacitinib